Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Restructuring programme
Restructuring and Related Cost, Cost Incurred to Date	$ 1,703	$ 2,285
Total amount expected to be incurred	$ 3,988
Percent of headcount reduction	25.00%
Contractual termination benefits
Restructuring programme
Restructuring and Related Cost, Cost Incurred to Date	$ 778	1,171
Total amount expected to be incurred	1,949
One-time employee termination benefits
Restructuring programme
Restructuring and Related Cost, Cost Incurred to Date	925	$ 1,114
Total amount expected to be incurred	$ 2,039